The objective of this Non-Interventional study is to evaluate the effectiveness \& safety of Nexavar in advanced Renal Cell Carcinoma (RCC) patients under daily-life treatment conditions based on age of the patient (older (age \>70 years) and younger patients (age \<70 years). Specifically investigated are the tumor status, duration of Nexavar ® treatment (number of cycles) and incidence of Hand foot Skin Reaction.
Study Type
OBSERVATIONAL
The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
Efficacy related variables are status of tumor / metastases.
Time frame: After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)
Efficacy related variables are patient's performance status.
Time frame: After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)
Efficacy related variables are efficacy assessment by the physician.
Time frame: After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)
Efficacy related variable - Quality of Life (QOL) assessment by the patient
Time frame: After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)
General tolerability assessment by physician and reports of adverse events.
Time frame: After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.